Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Feature|Articles|November 4, 2026
DLL3-Targeted Therapy and KRAS Inhibition Lead Lung Cancer Data Highlights From ESMO 2026
Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Advertisement
Advertisement
As data emerged across the lung cancer treatment paradigm at the
Related to this article
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.
Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.
Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.
Advertisement
Advertisement